Innovent says Takeda wins Japan SAKIGAKE designation for gastric cancer drug Arcotatug Tavatecan
TAK•
TAK•Takeda received Japan’s SAKIGAKE designation for arcotatug tavatecan, which is being developed for certain advanced gastric and gastroesophageal junction cancers. The designation provides eligibility for priority regulatory consultation and review in Japan.
Innovent Biologics announced on Nov. 17, 2026, that Takeda received Japan’s SAKIGAKE designation for arcotatug tavatecan (IBI343/TAK-921). The proposed indication covers CLDN18.2-positive unresectable advanced or recurrent gastric or gastroesophageal junction adenocarcinoma that progresses after chemotherapy.
The designation provides eligibility for priority regulatory consultation and priority review in Japan. The supporting Phase 3 G-HOPE-001 trial, conducted in China and Japan, demonstrated meaningful survival benefits, delayed disease progression and a superior safety profile; results were presented at the 2026 European Society for Medical Oncology Congress.